Follistatin
What the Research Actually Shows
Human: 1 studies, 5 groups · Animal: 2 · In Vitro: 2
The myostatin blocker with real gene therapy data in muscular dystrophy — and why injecting a complex glycoprotein from a research chemical vendor is a fundamentally different proposition
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Follistatin is a large protein your body naturally makes to control muscle growth. It works by blocking myostatin — the molecule that acts as a brake on how big your muscles can get. Remove the brake, and muscles grow. In a small gene therapy trial, six patients with muscular dystrophy received follistatin delivered directly into their muscles by a virus that made their cells produce it continuously. Two patients walked farther. Muscle biopsies looked better. No serious side effects. That's the good news. Here's the catch: the community version — injecting a synthetic copy of this protein from a research chemical vendor — is a completely different approach. Gene therapy produces the protein continuously inside muscle cells. Injection delivers a burst that's cleared within hours. The protein itself is 35,000 daltons and requires correct folding and sugar attachments to work — far harder to manufacture than a simple peptide. And the broader story of myostatin-blocking drugs is one of repeated clinical failure.
Follistatin occupies a unique position among performance-oriented compounds. It has the strongest mechanistic foundation in Performance and Body Composition — myostatin is genuinely the master negative regulator of skeletal muscle mass, and follistatin is the body's natural mechanism for neutralizing it. It has human clinical data — a Phase 1/2a gene therapy trial in Becker muscular dystrophy that showed improved ambulation and histological evidence of muscle repair (PMID 25322757). And it has the most cautionary translation gap of any compound in the cluster.
The gene therapy trial used AAV1.CMV.FS344 — an adeno-associated viral vector that was injected directly into quadriceps muscle, where it transduced cells to produce follistatin continuously from within. This is not analogous to injecting recombinant follistatin protein subcutaneously. The pharmacokinetics are incompatible: gene therapy produces sustained local expression over months or years; injected protein is cleared within hours. The dose-response relationship established in gene therapy trials cannot be transferred to injection protocols.
Follistatin is also not a peptide. It is a 35–40 kDa glycoprotein — a large, complex molecule requiring correct disulfide bonding and glycosylation (sugar chain attachment) for biological activity. Manufacturing it correctly is orders of magnitude harder than synthesizing a 5–15 amino acid peptide. Research chemical vendors selling "follistatin" may or may not be delivering the correctly folded, glycosylated, bioactive protein.
This article examines the genuine science behind follistatin, the gene therapy evidence that gives it credibility, the sobering record of myostatin inhibitor failures in clinical trials, and the honest assessment of what injectable recombinant follistatin can and cannot be expected to do.
In This Article
Quick Facts: Follistatin at a Glance
Type
Complex glycoprotein (344 or 315 amino acids) — NOT a peptide
Also Known As
FS344, FS315, FS288, follistatin-344, follistatin-related gene, ACE-031 (unrelated anti-myostatin)
Generic Name
Follistatin (no INN for the injectable form; gene therapy vector: AAV1.CMV.FS344)
Brand Name
None for injectable. Gene therapy vector under IND review (not commercially available)
Active Fragment
Full protein required for activity. Follistatin-derived peptide fragments (PMID 19108572) show partial activity in mice but are not the community product
Related Compounds
Myostatin (target), MYO-029/stamulumab (failed myostatin antibody), domagrozumab (failed), bimagrumab (activin inhibitor, failed in MD)
Molecular Weight
~35,000–40,000 Da (glycosylated) — roughly 40x larger than typical community peptides
Peptide Sequence
344 amino acids (FS344) or 315 amino acids (FS315 — locally processed isoform). Three follistatin domains. Not a peptide — a full protein
Endogenous Origin
Yes — ubiquitously expressed in muscle, liver, skin, and other tissues. Originally isolated from ovarian follicular fluid
Primary Molecular Function
Binds and neutralizes myostatin (GDF-8), activins, and other TGF-β superfamily ligands, removing the primary negative regulator of skeletal muscle mass
Half-Life
Recombinant protein: estimated minutes to hours (rapid renal clearance). Gene therapy: continuous expression from transduced cells (months to years)
Clinical Programs
AAV1.CMV.FS344 gene therapy: Phase 1/2a for Becker Muscular Dystrophy (NCT01519349). No clinical program for injectable protein
Route
Direct intramuscular injection of AAV vector (clinical trial); subcutaneous/intramuscular injection of recombinant protein (community use)
Community Interest
Muscle hypertrophy, myostatin suppression, body composition optimization, anti-aging. "Remove the brake on muscle growth" narrative drives community adoption
FDA Status
Not approved. Gene therapy vector has IND status for Becker MD. Injectable protein is not a pharmaceutical product
WADA Status
Prohibited under S4.5: Myostatin Inhibitors. Follistatin and gene doping with follistatin vectors both prohibited
Evidence Tier
~ It's Complicated
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Follistatin?
Pronunciation: foh-LIS-tah-tin
Your muscles want to grow. Left entirely to their own devices — flooded with growth factors, loaded with satellite cells, stimulated by training — skeletal muscle would expand dramatically. The reason it doesn't is a molecule called myostatin, also known as GDF-8. Myostatin is the brake. It signals through the ActRIIB receptor to actively suppress muscle protein synthesis, satellite cell activation, and fiber hypertrophy. Animals born without functional myostatin — the famous Belgian Blue cattle, the "bully whippets," myostatin-knockout mice — develop dramatic, visibly exaggerated musculature.
Follistatin is the body's answer to myostatin. It's a large glycoprotein, originally identified in ovarian follicular fluid (hence "follicle-statin"), that binds myostatin with high affinity and neutralizes it. When follistatin grabs myostatin, myostatin cannot reach its receptor, and the brake on muscle growth is released. Follistatin also neutralizes activins — related TGF-β superfamily molecules that signal through the same receptor pathway — broadening its effects beyond pure myostatin inhibition.
The result is that follistatin has become the most mechanistically compelling compound in the performance community's toolkit. The logic is clean: block the brake, and the car goes faster. The challenge is that this clean logic has met messy clinical reality — not for follistatin specifically, but for the entire category of myostatin inhibitors, which have repeatedly failed in clinical trials.
PLAIN ENGLISH
Myostatin is the body's muscle growth limiter. Follistatin is the natural off switch for that limiter. Turn off the limiter, and muscles should grow more easily. This logic is sound — the problem is that multiple pharmaceutical companies have tried to exploit it, and most of their drugs have failed in human trials. The biology is real; the clinical translation has been disappointing.
Origins and Discovery
Follistatin was discovered not through muscle biology but through reproductive endocrinology. In the mid-1980s, researchers isolating factors from ovarian follicular fluid identified a protein that suppressed follicle-stimulating hormone (FSH) release from pituitary cells. They named it follistatin — "follicle" for its source, "statin" for its suppressive activity.
The connection to muscle came later, when myostatin was identified as the master negative regulator of muscle mass in the late 1990s. Se-Jin Lee's laboratory at Johns Hopkins demonstrated that myostatin knockout mice developed approximately twice the normal muscle mass. Subsequent work established that follistatin could neutralize myostatin, linking the reproductive biology discovery to the most commercially exciting target in muscle biology.
Jerry Mendell's laboratory at Nationwide Children's Hospital advanced the clinical application by developing an AAV1 vector carrying the FS344 gene under a CMV promoter. This vector was injected directly into the quadriceps muscles of Becker muscular dystrophy patients in the first human gene therapy trial targeting the myostatin pathway (NCT01519349).
The community adoption of injectable recombinant follistatin followed the typical research chemical pathway: the protein became available from research suppliers, the myostatin-blocking narrative was irresistible to the performance community, and adoption outpaced evidence for the specific use case.
Mechanism of Action
Myostatin Neutralization: The Primary Target
Myostatin (GDF-8) signals through the ActRIIB receptor complex (ActRIIB + ALK4/ALK5 co-receptor) to activate the Smad 2/3 pathway. Smad 2/3 signaling suppresses: - Satellite cell activation and proliferation - Myoblast differentiation and fusion - Muscle protein synthesis (via crosstalk with mTOR pathway) - Fiber hypertrophy
Follistatin binds myostatin with high affinity (Kd in the low nanomolar range), preventing it from engaging ActRIIB. This "de-repression" model means follistatin doesn't directly stimulate muscle growth — it removes the suppression that limits it. The distinction matters: follistatin creates permissive conditions for growth; actual growth still requires the usual anabolic stimuli (training, nutrition, growth factor signaling).
PLAIN ENGLISH
Follistatin doesn't push the gas pedal on muscle growth — it releases the parking brake. Your muscles still need all the normal growth signals (exercise, protein, hormones) to actually grow. Follistatin just removes the thing that was holding them back.
Activin Inhibition: Broader Effects
Follistatin also binds and neutralizes activin A and activin B — TGF-β superfamily ligands that signal through the same ActRIIB pathway. Activin inhibition contributes to muscle hypertrophy (activins independently suppress muscle growth) and may affect: - FSH regulation (activins stimulate FSH secretion from the pituitary → follistatin may suppress FSH) - Bone metabolism (activin-mediated bone loss is blocked) - Inflammatory signaling (activins participate in tissue inflammation)
This broader activity profile means follistatin is not a pure myostatin inhibitor — it modifies the entire TGF-β superfamily signaling landscape, with potential off-target effects that pure myostatin antibodies don't have.
Gene Therapy vs. Injectable Protein: The Pharmacokinetic Chasm
This distinction is critical and explains why follistatin's evidence tier is "It's Complicated":
Gene therapy (clinical trial): An AAV vector transduces muscle cells to continuously produce follistatin from within. The protein is made locally, in the correct conformation, with proper glycosylation, at sustained physiological concentrations. Duration: months to years from a single injection.
Injectable protein (community use): Recombinant follistatin is injected subcutaneously or intramuscularly. The protein must survive the extracellular environment, diffuse to target tissues, and act before renal clearance eliminates it. Duration per dose: estimated hours. Requires repeated injections. Protein may not have correct folding or glycosylation depending on manufacturing source.
These are not two versions of the same thing. They are fundamentally different pharmacological approaches that happen to deliver the same protein.
PLAIN ENGLISH
Gene therapy is like installing a factory inside your muscles that makes follistatin 24/7. Injectable follistatin is like throwing the protein at your muscles from outside and hoping some of it sticks before your kidneys flush it out. The factory approach worked in a clinical trial. The throwing-from-outside approach has never been tested.
Mechanistic Comparison
vs. Myostatin antibodies (stamulumab, domagrozumab): These directly bind myostatin but don't affect activins. They have been tested in clinical trials and mostly failed — not because the mechanism is wrong, but because the muscle mass increases were clinically modest and didn't translate to functional improvement.
vs. Bimagrumab (activin receptor antibody): Blocks the ActRIIB receptor directly, preventing all ligands (myostatin, activins, GDF-11) from binding. Showed significant lean mass increases but failed primary endpoints in muscular dystrophy trials. Now being studied for obesity.
vs. IGF-1 variants (LR3, DES): Entirely different mechanism — IGF-1 variants directly stimulate growth through IGF-1R. Follistatin removes growth suppression. The approaches are complementary in theory, additive in risk.
Key Research Areas and Studies
The Gene Therapy Evidence (Human)
Mendell et al. (2015) published the results of the Phase 1/2a trial of AAV1.CMV.FS344 in Becker muscular dystrophy (PMID 25322757). Six patients received bilateral quadriceps injections of the vector at two dose levels.
Key results: - Patient 01 improved 58 meters on the 6-minute walk test (6MWT) - Patient 02 improved 125 meters on the 6MWT - Muscle biopsies showed reduced fibrosis, decreased central nucleation, and shift toward larger fiber diameter - No serious adverse events - No immune reaction to AAV1 or FS344 transgene product
A 2017 follow-up confirmed sustained ambulation improvements (PMC 5240576).
PLAIN ENGLISH
The gene therapy trial is the crown jewel of follistatin research. Six patients with muscular dystrophy got the treatment, and two of them could walk measurably farther. Their muscle biopsies looked healthier — less scarring, bigger muscle fibers. And nobody got seriously hurt. That's encouraging data from a real human trial.
But the critical caveat: This was gene therapy in disease patients, not injectable protein in healthy adults. The delivery mechanism, pharmacokinetics, population, and clinical context are all different from the community use case.
The Myostatin Inhibitor Failure Record
Multiple pharmaceutical myostatin inhibitors have failed or produced disappointing results in clinical trials (PMC 7764137):
- Stamulumab (MYO-029): Anti-myostatin antibody tested in muscular dystrophy. Phase II showed no significant improvement in muscle strength or function.
- Domagrozumab: Anti-myostatin antibody tested in Duchenne MD. Phase II failed primary endpoint.
- Bimagrumab: Anti-ActRIIB antibody. Increased lean mass by ~6% in sarcopenia trials but failed functional endpoints in muscular dystrophy.
Follistatin is not equivalent to these drugs — it works through a different mechanism (binding myostatin + activins vs. blocking the receptor) and was delivered differently (gene therapy vs. injection). But the broader pattern is cautionary: blocking the myostatin pathway has consistently produced less dramatic human results than animal models predicted.
PLAIN ENGLISH
Drug companies have spent billions trying to exploit the myostatin pathway. Most of their drugs increased muscle mass a bit but didn't make patients stronger or more functional. This doesn't mean myostatin blocking doesn't work — it means the leap from "bigger muscles" to "better function" is harder than anyone expected.
Follistatin-Derived Peptides
Nakatani et al. (2008) showed that follistatin-derived peptide fragments ameliorated pathology in mdx mice (the standard Duchenne MD model) (PMID 19108572). This suggests that smaller fragments of follistatin retain partial myostatin-neutralizing activity — an interesting finding for drug development, though the community product is the full recombinant protein, not a peptide fragment.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Follistatin blocks myostatin"” | Fully established biochemistry. Follistatin binds myostatin with high affinity and prevents ActRIIB signaling. This is not in dispute. | Supported |
| “"Blocking myostatin leads to massive muscle growth"” | Dramatic in animal knockouts (Belgian Blue cattle, myostatin-null mice). Modest in human clinical trials with myostatin inhibitors — 3–6% lean mass increases without functional improvements. | Mixed Evidence |
| “"Follistatin gene therapy worked in humans"” | Phase 1/2a trial: 6 Becker MD patients, improved 6MWT distance, improved histology, no serious AEs (PMID 25322757). Small, uncontrolled, in a disease population — but genuine human evidence. | Supported |
| “"Injectable recombinant follistatin builds muscle"” | Zero human data for injectable follistatin. The gene therapy evidence cannot be transferred — different pharmacokinetics, different delivery, different dose-response. | Preclinical Only |
| “"Follistatin is a peptide"” | Follistatin is a 35–40 kDa glycoprotein — roughly 40x larger than a typical community peptide. It requires correct disulfide bonding and glycosylation. Calling it a "peptide" misrepresents its manufacturing complexity. | Unsupported |
| “"Research chemical follistatin is bioactive"” | No independent quality analysis of commercial recombinant follistatin products has been published. Complex glycoprotein manufacturing is orders of magnitude harder than peptide synthesis. Product quality is uncertain. | Theoretical |
| “"Follistatin will produce myostatin knockout–like results"” | Myostatin knockouts develop extreme musculature through lifelong absence of the gene. Exogenous follistatin produces transient, partial myostatin suppression. These are not comparable scenarios. | Unsupported |
| “"Cycling follistatin subcutaneously is equivalent to the gene therapy results"” | The gene therapy produced continuous local expression over months. SC injection provides hours of systemic exposure. The pharmacokinetics are incompatible. | Unsupported |
| “"Follistatin has no significant side effects"” | The gene therapy trial (6 patients) reported no serious AEs. But: (1) N=6 is too small to detect uncommon events, (2) injectable protein in healthy adults is untested, (3) activin suppression may disrupt FSH and reproductive function, (4) chronic myostatin suppression may harm cardiac muscle. | Mixed Evidence |
| “"Combining follistatin with IGF-1 variants creates synergistic growth"” | Mechanistically plausible — removing myostatin suppression + adding IGF-1R stimulation. But untested in any species for this specific combination. Additive risk without proven additive benefit. | Theoretical |
| “"Myostatin inhibitors don't work — the clinical trials proved it"” | Clinical failures were with antibodies and receptor blockers, not follistatin. Follistatin has broader activity (activin + myostatin) and was delivered by gene therapy, not injection. The failures are cautionary but not directly applicable. | Mixed Evidence |
| “"Follistatin is safe because it's a natural body protein"” | Many natural proteins are toxic at supraphysiological levels. Follistatin's activin-neutralizing activity could disrupt FSH regulation (reproductive function) and bone metabolism. Long-term myostatin suppression may harm cardiac muscle. | Mixed Evidence |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
The human evidence landscape for follistatin is genuinely complicated — which is why it earns the Tier ~ designation.
What exists: A Phase 1/2a gene therapy trial (PMID 25322757) delivered AAV1.CMV.FS344 to 6 Becker muscular dystrophy patients by direct bilateral intramuscular quadriceps injection. Two patients improved on the 6-minute walk test (58 and 125 meters). Muscle biopsies showed reduced fibrosis and larger fiber diameters. A 2017 follow-up confirmed sustained improvements (PMC 5240576). No serious adverse events.
What this tells us: Follistatin protein, produced continuously inside muscle cells from a viral vector, can improve muscle function in a degenerative muscle disease. The mechanism (myostatin/activin neutralization → muscle de-repression) translates from animals to humans via gene therapy.
What this doesn't tell us: Whether injected recombinant follistatin protein — with different pharmacokinetics, different dosing, in a different population — produces any measurable effect. The gene therapy and injectable protein approaches share a mechanism but differ in every other pharmacological parameter.
The Translation Gap: Three Disconnects
Disconnect 1: Delivery. Gene therapy transduces muscle cells to produce follistatin continuously, locally, in correctly folded and glycosylated form. Injection delivers a bolus that is systemically distributed, rapidly cleared, and potentially misfolded or under-glycosylated.
Disconnect 2: Population. The trial enrolled Becker MD patients — individuals with documented muscle pathology where the therapeutic potential (de-repressing growth in diseased tissue) is clinically meaningful. Community users are healthy adults seeking muscle enhancement beyond their genetic baseline — a different physiological scenario where the marginal benefit of myostatin suppression may be smaller.
Disconnect 3: Dose-response. Gene therapy produces picomolar to nanomolar follistatin concentrations continuously. Injected protein produces a brief spike of uncertain tissue concentration followed by rapid clearance. Whether the transient exposure from injection is sufficient to meaningfully suppress myostatin signaling has not been tested.
The Broader Myostatin Inhibitor Record
The clinical failure of pharmaceutical myostatin inhibitors (stamulumab, domagrozumab, bimagrumab) provides important context. These drugs successfully increased lean mass in clinical trials — but lean mass increases of 3–6% did not translate to functional improvement in strength or ambulation. The myostatin hypothesis is not wrong; the translation is harder than predicted.
PLAIN ENGLISH
Follistatin is the rare Tier ~ compound — it genuinely has human data, but from a treatment so different from what the community does that the data can't be simply transferred. Gene therapy puts a follistatin factory inside your muscle. Injection throws the protein at your muscle and hopes for the best. One worked in six patients. The other has never been tested.
Safety, Risks, and Limitations
Reproductive Axis Disruption
Follistatin neutralizes activins, which regulate FSH secretion from the anterior pituitary. Chronic activin suppression could disrupt the hypothalamic-pituitary-gonadal axis, potentially affecting fertility, spermatogenesis in males, and follicular development in females. This risk has not been characterized for exogenous follistatin administration.
CRITICAL DISCLAIMER
Follistatin's activin-neutralizing activity may suppress FSH and disrupt reproductive function. This effect is mechanistically predicted but clinically uncharacterized. Anyone considering follistatin use should be aware of potential fertility impacts.
Cardiac Muscle Concerns
Myostatin appears to serve a protective function in cardiac muscle. Myostatin-null mice develop cardiac dysfunction, and chronic myostatin suppression may promote pathological cardiac hypertrophy rather than the adaptive hypertrophy seen with exercise. This is a theoretical but mechanistically grounded concern.
PLAIN ENGLISH
Myostatin doesn't just limit skeletal muscle growth — it also helps keep your heart from growing too much. Blocking myostatin long-term might cause your heart to enlarge in unhealthy ways. This hasn't been proven in humans, but it's based on what happens in mice that completely lack myostatin.
Immunogenicity
Follistatin is a large protein. Repeated injection of large exogenous proteins carries a risk of antibody development — the immune system recognizes the protein as foreign and mounts a response. Anti-follistatin antibodies could neutralize both the injected protein and (theoretically) endogenous follistatin, paradoxically increasing myostatin activity. This risk is standard for large-molecule biologics and has not been studied for recombinant follistatin.
Product Quality: A Glycoprotein Problem
This is perhaps the most underappreciated risk. Follistatin is a ~35–40 kDa glycoprotein requiring: - Correct disulfide bonding (multiple disulfide bridges across three follistatin domains) - Proper N-linked glycosylation (sugar chain attachment that affects protein folding, stability, and receptor binding) - Correct tertiary structure (three-dimensional folding)
Manufacturing a correctly folded, glycosylated protein at this scale requires mammalian cell expression systems (CHO cells, HEK293 cells) — not the bacterial expression or chemical synthesis used for simple peptides. Research chemical vendors may produce follistatin in bacterial systems (E. coli), which cannot glycosylate proteins. The result could be a correctly sequenced but improperly folded, unglycosylated protein with reduced or absent biological activity.
PLAIN ENGLISH
Follistatin is roughly 40 times larger than most peptides people inject. Making it correctly requires specialized equipment that can add sugar chains and fold the protein into the right shape. If a vendor makes it the cheap way, you may get a blob of protein that has the right amino acid sequence but the wrong three-dimensional shape — and shape is what determines whether a protein works.
Rapid Clearance
Recombinant follistatin, when correctly produced, is still a protein subject to renal filtration and peptidase degradation. The estimated half-life of hours means that any myostatin-suppressive effect from a single injection is transient. The community response — frequent injections — amplifies cost, injection-related risks, and immune exposure without established dose-response data.
Legal and Regulatory Status
Follistatin's regulatory landscape is bifurcated:
Gene therapy (AAV1.CMV.FS344): Has IND status with the FDA for Becker muscular dystrophy (NCT01519349). This is a regulated pharmaceutical development program under standard FDA oversight.
Injectable recombinant protein: Not approved by the FDA. Not a pharmaceutical product. Sold as a research chemical. No regulatory pathway has been pursued for the injectable form.
WADA prohibits follistatin under category S4.5 (Myostatin Inhibitors). Gene doping with follistatin vectors is also specifically prohibited. The prohibition covers any method of increasing follistatin activity, whether by protein injection or genetic modification.
Research Protocols and Formulation Considerations
No published protocol exists for human administration of injectable recombinant follistatin. The gene therapy protocol (Mendell et al., 2015) used direct bilateral quadriceps injection of AAV1 vector at 3 × 10¹¹ or 6 × 10¹¹ vector genomes per leg — a protocol that is not relevant to recombinant protein injection.
Recombinant follistatin is typically supplied lyophilized. Reconstitution with bacteriostatic water at 2–8°C (35–46°F). The glycoprotein nature of follistatin makes it more sensitive to handling than small peptides — vigorous agitation, temperature fluctuations, or prolonged storage in solution may cause aggregation, denaturation, or loss of glycosylation-dependent activity.
Dosing in Published Research
WHY NO DOSING CHART?
No published dose-response study exists for Follistatin. The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
No published dose-response study exists for injectable recombinant follistatin in any species for muscle growth or body composition.
Gene therapy dosing (reference only — not transferable to protein injection): Mendell et al. used 3 × 10¹¹ or 6 × 10¹¹ vector genomes per quadriceps, delivered by direct intramuscular injection. This produced sustained local follistatin expression at physiological concentrations.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Follistatin has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
The following table summarizes community-reported dosing practices for Follistatin. These are not clinical recommendations. No controlled trial data supports these protocols.
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Subcutaneous | Systemic myostatin suppression | No published evidence | 100–300 mcg/day | Rapid clearance, immunogenicity, reproductive axis disruption, product quality unknown |
| Intramuscular (site-specific) | Localized myostatin suppression at target muscle | No published evidence | 100–200 mcg per site | Same risks plus local immune reaction to large protein |
| Cycle length | 10–30 days, with variable off periods | No published evidence | — | No basis for any cycling protocol |
Community protocols often combine follistatin with IGF-1 variants (LR3, DES) or GH secretagogues, based on the logic of simultaneously removing the growth brake (follistatin) and amplifying the growth signal (IGF-1). No published study has tested any combination protocol.
PLAIN ENGLISH
Every number in the table above is from forums. No scientist has ever tested what dose of injectable follistatin a human needs, how often to inject it, or how long to cycle it. The doses people use were essentially invented by early adopters and have been repeated without verification.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Follistatin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Follistatin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| IGF-1 LR3 | 83-AA engineered IGF-1 variant (long-acting) | Tier 4 — Preclinical Only | Eyes Open | IGF-1R → PI3K/Akt/mTOR; evades IGFBPs via Arg3→Glu substitution in E-extension; ~2.5× potency of native IGF-1 | Muscle hypertrophy; fat loss; recovery | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Zero human data; same mitogenic pathway that drives cancer; product authenticity variable |
| IGF-1 DES | 67-AA truncated IGF-1 variant (short-acting) | Tier 4 — Preclinical Only | Eyes Open | IGF-1R → PI3K/Akt/mTOR; lacks N-terminal tripeptide → cannot bind IGFBPs; ~10× IGF-1R affinity; rapid clearance (~20–30 min) | Local muscle growth (site injection); fat loss | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Zero human data; extremely short half-life requires precise timing; same cancer-risk axis as LR3 |
| MGF / PEG-MGF | 24-AA E-peptide from IGF-1Ec splice variant (± PEG) | Tier 4 — Preclinical Only | Thin Ice | Proposed: satellite cell activation via E-peptide signaling independent of IGF-1R; PEG extends half-life. Disputed — one key study showed no effect on myoblasts | Muscle repair; satellite cell activation; recovery | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Free MGF E-peptide never isolated from biological fluids; fundamental bioactivity disputed; key negative study (PMID 24253050) |
| Follistatin | 344-AA glycoprotein (~35–40 kDa) | Tier ~ — It's Complicated | Eyes Open | Binds and neutralizes myostatin (GDF-8) + activins → derepression of Smad 2/3 → satellite cell activation → muscle hypertrophy | Muscle growth (myostatin blockade); muscular dystrophy gene therapy | 6 patients in 1 open-label gene therapy trial (Becker MD) | Not approved (IND for gene therapy) | Prohibited (S4.5 — Myostatin Inhibitors) | Human data is gene therapy only — not injectable protein; complex glycoprotein hard to manufacture correctly; broader myostatin inhibitor clinical programs have failed |
Frequently Asked Questions
Is follistatin a peptide?
No. Follistatin is a 35–40 kDa glycoprotein — roughly 40 times larger than a typical peptide. It requires correct disulfide bonding and glycosylation to function. This makes it fundamentally more complex to manufacture than the 5–15 amino acid peptides commonly used in the community.
Has follistatin been tested in humans?
Yes — as gene therapy, not as injectable protein. A Phase 1/2a trial (PMID 25322757) delivered follistatin via an AAV viral vector to 6 Becker muscular dystrophy patients. Two patients improved on the 6-minute walk test. Muscle biopsies showed reduced fibrosis and larger fibers. But this was continuous local expression from gene therapy — pharmacologically different from injecting recombinant protein.
Why is follistatin rated Tier ~ instead of Tier 2?
Because the human clinical data (gene therapy in muscular dystrophy) cannot be cleanly mapped to the community use case (injectable protein in healthy adults). The mechanism was tested, but through a fundamentally different delivery method in a different population. Tier 2 requires clinical data that reasonably informs the community use case; Tier 4 doesn't acknowledge that human data exists at all. Tier ~ captures this complexity.
Do myostatin inhibitors work?
In animals: dramatically. Myostatin-null mice have twice the normal muscle mass. In humans: modestly. Clinical trials with myostatin antibodies showed 3–6% lean mass increases but generally failed to improve muscle function. The biology is real; the human translation has been disappointing.
Can I get the same results as the gene therapy trial by injecting recombinant follistatin?
Almost certainly not. Gene therapy produces continuous, local follistatin expression for months. Injection produces a brief spike that's cleared in hours. The dose-response relationships are incompatible. To approximate continuous expression, you would need to inject frequently — compounding cost, immune risk, and injection-related risks without established efficacy.
Is research chemical follistatin likely to be bioactive?
Uncertain. Correct glycoprotein manufacturing requires mammalian cell expression systems. If a vendor produces follistatin in bacteria (E. coli), the protein will lack glycosylation and may be incorrectly folded. No independent quality analysis of commercial recombinant follistatin products has been published.
Could follistatin affect fertility?
Yes — theoretically. Follistatin neutralizes activins, which regulate FSH secretion. Chronic activin suppression could disrupt the reproductive axis in both males and females. This has not been characterized in humans receiving exogenous follistatin.
Does follistatin carry a cancer risk?
The myostatin/activin suppression pathway is not directly mitogenic in the way IGF-1R stimulation is. However, myostatin and activins play roles in tumor suppression in some tissues, and chronic suppression could theoretically promote tumor growth. This risk is less well-defined than the cancer risk from IGF-1 variants but cannot be excluded.
Why have pharmaceutical myostatin inhibitors failed?
The primary issue is the gap between lean mass increases and functional improvement. Drugs like stamulumab and domagrozumab increased muscle mass but didn't make patients with muscular dystrophy significantly stronger or more functional. The reasons are debated — possible explanations include inadequate muscle quality improvement, compensation by other TGF-β ligands, or baseline muscle damage too severe to overcome.
How does follistatin compare to IGF-1 LR3 and DES?
Different mechanism entirely. IGF-1 variants directly stimulate growth through IGF-1R. Follistatin removes growth suppression by neutralizing myostatin. They're complementary in theory — one pushes the gas, the other releases the brake. In practice, neither has been tested in humans for performance, and combining them compounds risk without evidence of synergistic benefit.
Is the follistatin gene therapy available to the public?
No. The AAV1.CMV.FS344 vector is available only through the clinical trial (NCT01519349) at Nationwide Children's Hospital. Gene therapy vectors are not commercially available, require specialized manufacturing, and are administered under medical supervision with immunosuppression protocols.
What should I watch out for if I use follistatin?
Signs of reproductive disruption (changes in menstrual cycle, changes in libido, fertility concerns). Signs of immune reaction to the protein (swelling, redness, or warmth at injection sites that worsens with repeated use). Any unusual cardiac symptoms. These would warrant immediate medical consultation and disclosure of follistatin use.
Summary of Key Findings
Follistatin has the strongest mechanistic foundation in Performance and Body Composition. Myostatin is genuinely the master negative regulator of skeletal muscle mass, follistatin is the body's natural mechanism for neutralizing it, and the biology is validated from knockout animals to human gene therapy.
The gene therapy data in Becker muscular dystrophy is the compound's most significant credential: improved ambulation, improved histology, no serious adverse events in a Phase 1/2a trial. This is real human evidence for follistatin's biological activity.
The translation gap is also the compound's most significant limitation. Gene therapy produces continuous local protein expression; injection produces transient systemic exposure. Manufacturing a correctly folded, glycosylated 35–40 kDa protein is fundamentally more complex than synthesizing small peptides. The broader record of myostatin inhibitor clinical failures — modest lean mass gains without functional improvement — tempers expectations.
For the community use case (injectable recombinant protein for muscle enhancement), the honest assessment is: the mechanism is the best in the cluster, the gene therapy data provides credibility that most Tier 4/~ compounds lack, but the specific intervention (injection of uncertain-quality recombinant protein with rapid clearance) has zero human evidence and faces multiple pharmacological barriers to replicating the gene therapy results.
PLAIN ENGLISH
Follistatin is the compound with the best story and the biggest gap between the story and what people actually do. The science is real — myostatin blocking works. The gene therapy data is encouraging. But injecting a complex protein from a research chemical vendor is not gene therapy, and the pharmaceutical track record of myostatin-blocking drugs should moderate expectations. The mechanism earns respect. The specific community protocol earns caution.
Verdict Recapitulation
Follistatin cannot be placed in a clean tier. Human data exists (gene therapy, Becker MD), but through a delivery mechanism so different from community use that direct translation is inappropriate. The mechanism is the strongest in the cluster. The pharmaceutical translation record is humbling. The product quality challenges for a complex glycoprotein are real. Eyes Open reflects the genuine complexity: proceed with informed understanding of both the compound's unique strengths and its unique limitations.
For readers considering Follistatin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Follistatin
Further Reading and Resources
If you want to go deeper on Follistatin, the evidence landscape for performance & body composition peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Performance & Body Composition Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Follistatin — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Mendell JR, Sahenk Z, Malik V, et al. (2015). "A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy." Mol Ther, 23(1), 192–201. PMID 25322757
- Mendell JR, Sahenk Z, Al-Zaidy S, et al. (2017). "Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes." Mol Ther, 25(4), 870–879. PMC: 5240576
- Suh J, Lee YS. (2020). "Myostatin inhibitors: panacea or predicament for musculoskeletal disorders?" J Bone Metab, 27(3), 151–165. PMC: 7764137
- Nakatani M, Takehara Y, Sugino H, et al. (2008). "Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice." FASEB J, 22(2), 477–487. PMID 19108572
- Rodino-Klapac LR, Haidet AM, Kota J, et al. (2009). "Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease." Muscle Nerve, 39(3), 283–296. PMID 19208403
- Pearsall RS, Davies MV, Cannell M, et al. (2025). "Therapeutic myostatin inhibition: challenges and opportunities." Nat Rev Drug Discov, 24, 123–138. PMC: 11842502
- ClinicalTrials.gov. NCT01519349. "Follistatin Gene Therapy for Becker Muscular Dystrophy." Nationwide Children's Hospital
DISCLAIMER
Follistatin is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.